Ulcerative Colitis Market 2016 Pipeline Review of 108 Companies

PUNE, India, May 30, 2016 /PRNewswire/ --

LifeScienceIndustryResearch.com adds "Ulcerative Colitis - Pipeline Review, H1 2016" market research report with comprehensive information on the therapeutic development for Ulcerative Colitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ulcerative Colitis and special features on late-stage and discontinued projects.

Complete report on H1 2016 pipeline review of Ulcerative Colitis with 109 market data tables and 15 figures, spread across 260 pages is available at http://www.lifescienceindustryresearch.com/ulcerative-colitis-pipeline ... .

The report also reviews key players involved in the therapeutic development for Ulcerative Colitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies discussed in this Ulcerative Colitis Pipeline Review, H1 2016 report include 4D Pharma Plc, AbbVie Inc., Advinus Therapeutics Ltd., Ajinomoto Pharmaceuticals Co., Ltd., Am-Pharma B.V., Amgen Inc., Arena Pharmaceuticals, Inc., Atlantic Healthcare Plc, Avaxia Biologics, Inc., BioAtla, LLC, Bionovis SA, Celgene Corporation, Cellceutix Corporation, ChemoCentryx, Inc., ChironWells GmbH, Chong Kun Dang Pharmaceutical Corp., Coherus BioSciences, Inc., Cosmo Pharmaceuticals S.p.A, Dr. Falk Pharma GmbH, Effimune S.A., Eli Lilly and Company, Enceladus Pharmaceuticals BV, enGene, Inc, Enterome Bioscience SA, Epirus Biopharmaceuticals, Inc., Flexion Therapeutics, Inc., Genentech, Inc., Genor BioPharma Co., Ltd., Gilead Sciences, Inc., GlaxoSmithKline Plc, GW Pharmaceuticals Plc, iCo Therapeutics Inc., Idera Pharmaceuticals, Inc., InDex Pharmaceuticals AB, Innovate Biopharmaceuticals, Inc., INOXIA Lifesciences GmbH, Intas Pharmaceuticals Ltd., Invion Limited, Johnson & Johnson, Kaken Pharmaceutical Co., Ltd., Kymab Limited, Kyowa Hakko Kirin Co., Ltd., LIPID THERAPEUTICS GmbH, Mabion SA, Medestea Research & Production S.p.A., Mitsubishi Tanabe Pharma Corporation, Momenta Pharmaceuticals, Inc., Morphotek, Inc., Mycenax Biotech Inc., Oncobiologics, Inc., Pfizer Inc., Pluristem Therapeutics Inc., ProtAb Ltd, Protagonist Therapeutics Inc., Qu Biologics Inc., Re-Pharm Limited, Rebiotix Inc., Sandoz International GmbH, Seres Therapeutics, Inc., Sigmoid Pharma Limited, Stelic Institute & Co., Inc., sterna biologicals Gmbh & Co KG, Synergy Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Therapeutic Proteins International, LLC, Therapix Biosciences Ltd, Theravance Biopharma, Inc., Tillotts Pharma AG, Trino Therapeutics Limited and Ventria Bioscience.